Outpatient Oncology Infusion Market Analysis &
Forecast to 2030 by Key Players, Share, Trend, Segmentation 

The global outpatient oncology infusion market is expected to register commendable growth by 2030, due in part to the rising prevalence of cancer cases and growing investment interest towards R&D for cancer treatment worldwide.

Outpatient oncology infusion therapy is rapidly emerging as a major component of modern cancer treatment protocols. Infusion therapy refers to procedures where medicine is administered directly into the bloodstream of the patient to shrink or curb the growth of cancer cells.

Outpatient infusion therapies for cancer treatment encompass various services, including hormone therapy, immunotherapy, chemotherapy, and blood transfusions, as well as other infusion treatments the patient may require, like antibiotics, pain medication, and hydration fluids.

The global outpatient oncology infusion market is bifurcated in terms of product, application, therapy, mode, and region.

To access a sample copy or view the market report in detail along with the table of

contents, please click the link below: https://www.gminsights.com/request-sample/detail/5268

With respect to product, the outpatient oncology infusion industry is further classified into intravenous sets, infusion pumps, needleless connectors, and IV cannulas.

Of these, the IV cannulas segment registered revenues worth nearly $4 billion in 2021. This was credited largely to a rising adoption of IV cannulas for the infusion of medication or collection of blood samples in investigational medical processes.

Based on application, the outpatient oncology infusion market is segregated into liver cancer, lung cancer, prostate cancer, breast cancer, and others.

The liver cancer segment held a 3.9% share of the overall market in 2021, given the rapid rise in the prevalence of liver cancer, as well as the escalating demand for infusion therapies like targeted therapy or immunotherapy.

In February 2022, for instance, oncologists and surgeons at Penn Medicine's Department of Surgery used adjuvant hepatic artery infusion chemotherapy along with systemic chemotherapy, in order to treat unresectable CLMs (colorectal liver metastases) or mitigate the risk of recurrence among individuals with resected CLMs.

Browse key industry insights spread across 140 pages with 115 market data tables & 14 figures & charts from the report, “Outpatient Oncology Infusion Market Size By Product (Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors), By Application (Lung Cancer, Liver Cancer, Breast Cancer, Prostate Cancer), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy), By Mode (Intramuscular (IM), Intravenous (IV), Subcutaneous), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 – 2030” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/outpatient-oncology-infusion-market

From a therapy perspective, the outpatient oncology infusion industry is categorized into targeted therapy, immunotherapy, chemotherapy, and hormonal therapy. The hormonal therapy segment recorded a remuneration of over $6 billion in 2021, driven by the growing prevalence of cancer across the globe.

Additionally, rising awareness among patients and physicians regarding the benefits of alternative cancer treatments like hormone therapy is a major driver propelling industry growth.

With regard to mode, the overall outpatient oncology infusion market is divided into Intravenous (IV), Intramuscular (IM), Subcutaneous, and other.

In 2021, the intravenous (IV) segment accounted for almost 30.6% of the overall market share due to the rising occurrence of lung cancer, wherein IV solutions act as the primary source of energy for the patients. In addition, increasing rollout of intravenous (IV) products has also elevated the industry outlook.

In March 2022, for instance, a new therapy was approved by the FDA for the treatment of advanced prostate cancer metastasizing within the body. Known as Pluvicto, the therapy was designed to be administered via intravenous infusion, to identify and destroy tumors too small to be noticed through conventional medical imaging techniques.

On the regional front, the Latin America outpatient oncology infusion industry is poised to register a 12.2% CAGR through the forecast time period. This growth is mainly credited to technological advancements in the regional medical domain, and strong market players focus on developing novel and sophisticated outpatient oncology infusion therapies.

Partial Table of Contents (ToC) of the report:

Chapter 1   Methodology

1.1    Methodology

1.2    Market definitions

1.3    Forecast parameters

1.4    Data sources

1.4.1    Secondary

1.4.1.1   Paid sources

1.4.1.2   Unpaid sources

1.4.2    Primary

Chapter 2   Executive Summary

2.1    Outpatient oncology infusion industry 360° synopsis, 2017 - 2030

2.1.1    Business trends

2.1.2    Product trends

2.1.3    Application trends

2.1.4    Therapy trends

2.1.5    Mode trends

2.1.6    Regional trends

Browse complete table of content of this report@ https://www.gminsights.com/industry-analysis/outpatient-oncology-infusion-market

About Global Market Insights

Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:

Aashit Tiwari

Corporate Sales, USA

Global Market Insights Inc.

Toll Free: +1-888-689-0688

USA: +1-302-846-7766

Europe: +44-742-759-8484

APAC: +65-3129-7718

Email: sales@gminsights.com